8-acenaphthen-1-yl-1-(4-fluoro-phenyl)-1,3,8-triaza-spiro[4.5]decan-4-one | 247925-20-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 8-acenaphthen-1-yl-1-(4-fluoro-phenyl)-1,3,8-triaza-spiro[4.5]decan-4-one
• 英文别名: 8-(1,2-Dihydroacenaphthylen-1-yl)-1-(4-fluorophenyl)-1,3,8-triazaspiro[4.5]decan-4-one
• CAS: 247925-20-8
• 化学式: C₂₅H₂₄FN₃O
• 分子量: 401.483
• InChiKey: KJXGSCVSIAVYKU-UHFFFAOYSA-N

物化性质

• 沸点：
  658.1±55.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  30
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  35.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  8-acenaphthen-1-yl-1-(4-fluoro-phenyl)-1,3,8-triaza-spiro[4.5]decan-4-one 在 sodium hydride 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 19.5h， 生成 (R)-8-acenaphthen-1-yl-1-(4-fluorophenyl)-3-(2-(R)-oxiranyl-ethyl)-1,3,8-triazaspiro[4.5]decan-4-one
  参考文献：
  名称：

  [EN] HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS
  [FR] DERIVES DE 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE A SUBSTITUTION HYDROXYALKYLE UTILES POUR TRAITER DES MALADIES ASSOCIEES AU RECEPTEUR ORL-1

  摘要：

  公开号：

  WO2004022558A3
• 作为产物：
  描述：

  (RS)-4-(4-fluoro-phenylamino)-1-(acenaphthen-1-yl)-piperidine-4-carbonitrile 在 sodium tetrahydroborate 、 甲酸 、 乙酸酐 、 溶剂黄146 、 原甲酸三乙酯 作用下， 生成 8-acenaphthen-1-yl-1-(4-fluoro-phenyl)-1,3,8-triaza-spiro[4.5]decan-4-one
  参考文献：
  名称：

  8-Acenaphthen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as orphanin FQ receptor agonists

  摘要：

  A series of 8-acenaphthen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one derivatives 1 was studied with respect to the binding affinity for the orphanin FQ (OFQ) and opioid (mu, kappa, delta) receptors. The influence of stereochemistry as well as the substitution pattern of the phenyl-ring in position 1 on the affinity for the orphanin FQ receptor and selectivity to opioid (mu, kappa, delta) receptors is discussed. The most interesting compound Ic was tested for its anxiolytic-like properties in vivo. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00385-6

文献信息

• 1,3,8-TRISUBSTITUTED-1,3,8-TRIAZA-SPIRO[4.5]DECAN-4-ONE DERIVATIVES AS LIGANDS OF THE ORL-1 RECEPTOR
  申请人：BIGNAN Gilles C.

  公开号：US20080249122A1

  公开（公告）日：2008-10-09

  The present invention is directed to novel 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor.

  本发明涉及新颖的1,3,8-三取代-1,3,8-三氮杂螺[4.5]癸烷-4-酮衍生物，含有它们的药物组合物以及它们在治疗由ORL-1 G蛋白偶联受体介导的疾病和症状中的应用。
• Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1receptor mediated disorders
  申请人：——

  公开号：US20040142955A1

  公开（公告）日：2004-07-22

  The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula 1 wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain, migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.

  本发明涉及一种新型的羟基烷基取代的1,3,8-三氮杂螺[4.5]癸烷-4-酮衍生物，其一般式为1，其中所有变量如本文所定义，可用于治疗由ORL-1 G蛋白偶联受体介导的疾病和症状。特别地，本发明的化合物可用于治疗焦虑、抑郁、恐慌、痴呆、躁狂、双相情感障碍、物质滥用、神经病性疼痛、急性疼痛、慢性疼痛、偏头痛、哮喘、咳嗽、精神病、精神分裂症、癫痫、高血压、肥胖症、进食障碍、渴望、糖尿病、心律失常、肠易激综合征、克罗恩病、尿失禁、肾上腺疾病、注意力缺陷障碍（ADD）、注意力缺陷多动障碍（ADHD）、阿尔茨海默病，用于改善认知或记忆能力和情绪稳定。
• Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
  申请人：Battista Kathleen

  公开号：US20060030577A1

  公开（公告）日：2006-02-09

  The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain, migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.

  本发明涉及一种新的羟基烷基取代的1,3,8-三氮杂螺[4.5]癸酮衍生物，其通式如下： 其中所有变量如本文所定义，可用于治疗由ORL-1 G蛋白偶联受体介导的疾病和病症。更具体地，本发明的化合物可用于治疗焦虑、抑郁、惊恐、痴呆、躁狂、双相障碍、物质滥用、神经病性疼痛、急性疼痛、慢性疼痛、偏头痛、哮喘、咳嗽、精神病、精神分裂症、癫痫、高血压、肥胖症、进食障碍、渴望、糖尿病、心脏心律失常、肠易激综合征、克罗恩病、尿失禁、肾上腺疾病、注意力缺陷障碍（ADD）、注意力缺陷多动障碍（ADHD）、阿尔茨海默病，以改善认知或记忆，并用于情绪稳定。
• HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS
  申请人：BATTISTA Kathleen

  公开号：US20090124614A1

  公开（公告）日：2009-05-14

  The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain, migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.

  本发明涉及一种新型的羟基烷基取代的1,3,8-三氮杂螺[4.5]癸酮衍生物，其通式如下：其中所有变量均如本文所定义，可用于治疗由ORL-1 G蛋白偶联受体介导的疾病和症状。更具体地，本发明的化合物可用于治疗焦虑、抑郁、惊恐、痴呆、躁狂、双相情感障碍、物质滥用、神经病性疼痛、急性疼痛、慢性疼痛、偏头痛、哮喘、咳嗽、精神病、精神分裂症、癫痫、高血压、肥胖症、进食障碍、渴望、糖尿病、心律失常、肠易激综合征、克罗恩病、尿失禁、肾上腺疾病、注意力缺陷障碍（ADD）、注意力缺陷多动障碍（ADHD）、阿尔茨海默病，以改善认知或记忆，并用于情绪稳定。
• FLUORINE-ATOM-CONTAINING POLYMERIZABLE UNSATURATED-MONOMER, FLUORINE-ATOM-CONTAINING POLYMERIC COMPOUND AND PHOTORESIST RESIN COMPOSITION
  申请人：Koyama Hiroshi

  公开号：US20050282985A1

  公开（公告）日：2005-12-22

  A fluorine-atom-containing polymerizable unsaturated-monomer of the present invention is represented by the following formula (1a) or (1b): wherein each of a ring Z 1 and a ring Z 2 is an alicyclic carbon ring; when the alicyclic carbon ring is multi-cyclic, a part of atoms constituting the ring may be substituted by an oxygen atom, a sulfur atom or a nitrogen atom; an atom constituting the ring Z 1 and the ring Z 2 may have a substituent; each of R 1 , R 2 and R 3 is an alkyl group or a fluoroalkyl group; R is an specific unsaturated acyl group; provided that at least one of R 1 and R 2 is a fluorine atom or a fluoroalkyl group in the formula (1a), and in the formula (1b) (i) the ring Z 2 is bonded by a fluorine atom or a fluoroalkyl group, or (ii) R 3 is a fluoroalkyl group.

  本发明的含氟原子可聚合不饱和单体由下式(1a)或(1b)表示： 其中每个环 Z 1 和环 Z 2 为脂环碳环；当脂环碳环为多环时，构成环的部分原子可被氧原子、硫原子或氮原子取代；构成环 Z 1 和环 Z 2 中的每个 R 1 , R 2 和 R 3 是烷基或氟烷基； R 是特定的不饱和酰基；条件是 R 1 和 R 2 在式(1a)中至少有一个是氟原子或氟烷基，在式(1b)中 (i) 环 Z 2 由氟原子或氟烷基键合，或 (ii) R 3 是氟烷基。